1. Home
  2. CRVS vs CTKB Comparison

CRVS vs CTKB Comparison

Compare CRVS & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRVS
  • CTKB
  • Stock Information
  • Founded
  • CRVS 2014
  • CTKB 1990
  • Country
  • CRVS United States
  • CTKB United States
  • Employees
  • CRVS N/A
  • CTKB N/A
  • Industry
  • CRVS Biotechnology: Pharmaceutical Preparations
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • CRVS Health Care
  • CTKB Health Care
  • Exchange
  • CRVS Nasdaq
  • CTKB Nasdaq
  • Market Cap
  • CRVS 459.0M
  • CTKB 433.8M
  • IPO Year
  • CRVS 2016
  • CTKB 2021
  • Fundamental
  • Price
  • CRVS $8.79
  • CTKB $5.80
  • Analyst Decision
  • CRVS Strong Buy
  • CTKB Hold
  • Analyst Count
  • CRVS 4
  • CTKB 4
  • Target Price
  • CRVS $13.75
  • CTKB $5.88
  • AVG Volume (30 Days)
  • CRVS 1.0M
  • CTKB 1.8M
  • Earning Date
  • CRVS 11-04-2025
  • CTKB 11-05-2025
  • Dividend Yield
  • CRVS N/A
  • CTKB N/A
  • EPS Growth
  • CRVS N/A
  • CTKB N/A
  • EPS
  • CRVS N/A
  • CTKB N/A
  • Revenue
  • CRVS N/A
  • CTKB $196,828,000.00
  • Revenue This Year
  • CRVS N/A
  • CTKB N/A
  • Revenue Next Year
  • CRVS N/A
  • CTKB $7.25
  • P/E Ratio
  • CRVS N/A
  • CTKB N/A
  • Revenue Growth
  • CRVS N/A
  • CTKB N/A
  • 52 Week Low
  • CRVS $2.54
  • CTKB $2.37
  • 52 Week High
  • CRVS $9.55
  • CTKB $7.30
  • Technical
  • Relative Strength Index (RSI)
  • CRVS 63.66
  • CTKB 73.15
  • Support Level
  • CRVS $8.34
  • CTKB $5.15
  • Resistance Level
  • CRVS $9.22
  • CTKB $5.95
  • Average True Range (ATR)
  • CRVS 0.55
  • CTKB 0.46
  • MACD
  • CRVS 0.01
  • CTKB 0.10
  • Stochastic Oscillator
  • CRVS 83.41
  • CTKB 82.03

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Share on Social Networks: